Literature DB >> 1472830

Microalbuminuria is no risk factor for restenosis following percutaneous transluminal coronary angioplasty.

H Toplak1, M Schumacher, B Eber, O Luha, W Klein, G J Krejs.   

Abstract

Microalbuminuria is known to be associated with an increased risk for cardiovascular disease. It is detectable in acute myocardial infarction and could therefore also be a risk factor for reocclusion after percutaneous transluminal coronary angioplasty (PTCA). In our study follow-up coronary angiography was performed in 50 consecutive patients with a mean age of 56 years (38-70) on average 14 months after successful PTCA. Restenosis was defined as a decrease in diameter of 25% or more of the original result and one of at least 50% in vessel diameter. In the restenosis group there were 23 patients, and 27 showed no restenosis. The family history and anamnestic risk profile, results of the initially performed coronary angiography, and laboratory risk factors were comparable in the two groups. Median microalbumin was 11.2 mg/g creatinine in those with restenosis and 9.8 mg/g creatinine in those without. Using a cut-off of 10.0 mg/g creatinine, 12 of 23 patients with restenosis (52%) and 10 of 27 patients without (37%) were positive for microalbuminuria (NS). The incidence of microalbuminuria was higher in both groups compared to historical controls. Thus, in the restenosis group the incidence of microalbuminuria tended to be higher than in the nonrestenosis group, but since this difference did not reach statistical significance, it cannot be used to predict the risk of reocclusion after PTCA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1472830     DOI: 10.1007/bf00180310

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  16 in total

1.  Repeat coronary angioplasty for restenosis: results and predictors of follow-up clinical events.

Authors:  U Deligonul; M Vandormael; M J Kern; K Galan
Journal:  Am Heart J       Date:  1989-05       Impact factor: 4.749

2.  Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey.

Authors:  J S Yudkin; R D Forrest; C A Jackson
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

3.  Microalbuminuria as predictor of increased mortality in elderly people.

Authors:  E M Damsgaard; A Frøland; O D Jørgensen; C E Mogensen
Journal:  BMJ       Date:  1990-02-03

4.  Restenosis and progression of coronary atherosclerosis after coronary angioplasty.

Authors:  A Cequier; R Bonan; J Crépeau; G Coté; P De Guise; P Joly; J Lespérance; D D Waters
Journal:  J Am Coll Cardiol       Date:  1988-07       Impact factor: 24.094

5.  Immediate and long-term results of percutaneous transluminal coronary angioplasty. Comparison of the National Heart, Lung and Blood Institute Registry experience with current experience.

Authors:  L G Bentivoglio
Journal:  Herz       Date:  1985-10       Impact factor: 1.443

6.  Microalbuminuria is an early response following acute myocardial infarction.

Authors:  P Gosling; E A Hughes; T M Reynolds; J P Fox
Journal:  Eur Heart J       Date:  1991-04       Impact factor: 29.983

Review 7.  Albuminuria reflects widespread vascular damage. The Steno hypothesis.

Authors:  T Deckert; B Feldt-Rasmussen; K Borch-Johnsen; T Jensen; A Kofoed-Enevoldsen
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

8.  Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty.

Authors:  A R Grüntzig; A Senning; W E Siegenthaler
Journal:  N Engl J Med       Date:  1979-07-12       Impact factor: 91.245

9.  Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes.

Authors:  C E Mogensen
Journal:  N Engl J Med       Date:  1984-02-09       Impact factor: 91.245

Review 10.  Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia.

Authors:  M W Liu; G S Roubin; S B King
Journal:  Circulation       Date:  1989-06       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.